Suzanne Wombough
Family · Fort Worth, TXNPI 1124634621
Payments from drug & device makers
Across 233 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$673
- AstraZeneca$492
- Novo Nordisk$486
- Sanofi-aventis U.S. LLC$399
- Dexcom, Inc.$371
- Boehringer Ingelheim$245
- plus $2K from 27 others
Across 1 payment — averaging $126.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$126
What the payments were for
- Food & beverage$4,39899%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $673 |
| AstraZeneca(2 entities) | 24 | $492 |
| Novo Nordisk | 30 | $486 |
| Sanofi-aventis U.S. LLC | 20 | $399 |
| Dexcom, Inc. | 21 | $371 |
| Boehringer Ingelheim | 15 | $245 |
| Amarin Pharma, Inc. | 10 | $168 |
| Nevro Corp. | 2 | $168 |
| Clarus Therapeutics Inc. | 3 | $136 |
| Amgen | 7 | $129 |
| Alvogen Inc | 6 | $107 |
| Medtronic | 6 | $97 |
| Bayer | 6 | $95 |
| Mannkind Corporation | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 5 | $83 |
| Novartis | 3 | $79 |
| Insulet Corporation | 4 | $75 |
| Antares Pharma, Inc. | 4 | $72 |
| Corcept Therapeutics | 3 | $57 |
| Cequr Corporation | 3 | $53 |
| IBSA Pharma Inc. | 3 | $47 |
| Ultragenyx Pharmaceutical Inc. | 3 | $42 |
| Blueprint Medicines Corporation | 2 | $36 |
| Pfizer | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| AbbVie | 2 | $27 |
| Radius Health, Inc. | 1 | $26 |
| BETA Bionics, Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,434 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 207 | $362,840 |
| MounjaroTirzepatide | 88 | $137,166 |
| TrulicityDulaglutide | 43 | $75,307 |
| JardianceEmpagliflozin | 54 | $61,649 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $60,732 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $55,259 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $35,502 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $34,760 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $33,252 |
| FarxigaDapagliflozin Propanediol | 15 | $20,219 |
| KerendiaFinerenone | 15 | $19,023 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,532 |
| RybelsusSemaglutide | 11 | $17,329 |
| Novolog FlexpenInsulin Aspart | 24 | $16,181 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $9,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $486 | $380,169218 claims |
| Lilly USA, LLCMounjaro, Trulicity | $673 | $212,474131 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $245 | $94,90274 claims |
| AstraZenecaFarxiga | $492 | $20,21915 claims |
| BayerKerendia | $95 | $19,02315 claims |
| AbbVieSynthroid | $27 | $4,20260 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $1,18995 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.